Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2.00. The company’s shares closed yesterday at $1.32.

Pacific Biosciences of California, Inc. has a 52-week low of $1.16 and a 52-week high of $5.01. The company has a market cap of $366.98 million, a price-to-earnings ratio of -0.82 and a beta of 1.92.

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago.

In the last three months, 4 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find ...

Pacific Biosciences of California (PACB) ended the recent trading session at $1.22, demonstrating a +1.67% swing from the preceding day's closing price. The stock's change was less than the S&P 500's ...

For the quarter ended December 2024, Pacific Biosciences of California (PACB) reported revenue of $39.22 million, down 32.8% over the same period last year. EPS came in at -$0.20, compared to -$0. ...

PACB stock opened at $1.56 on Tuesday. Pacific Biosciences of California has a 12-month low of $1.16 and a 12-month high of $6.09. The company has a quick ratio of 8.64, a current ratio of 9.74 ...

MENLO PARK, Calif. (AP) — MENLO PARK, Calif. (AP) — Pacific Biosciences of California Inc. (PACB) on Thursday reported fourth-quarter profit of $3.6 million. The Menlo Park, California-based ...

(RTTNews) - Below are the earnings highlights for Pacific Biosciences of California, Inc. (PACB): Earnings: $3.57 million in Q4 vs. -$82.02 million in the same period last year. EPS: -$0.49 in Q4 vs.

For Asia-Pacific, revenue of approximately $8.9 million decreased 33% over the prior year, with sequential growth in consumables offset by lower Revio placements. Similar to the U.S., several ...